TickerFacts.

CG Oncology, Inc. (CGON): Cash & Equivalents

Annual figures by period end, from SEC filings.

$32.49M
As of 2025-12-31
$19.64M
As of 2026-06-30
$257.07M2023-12-31: $8.27M2024-12-31: $257.07M2025-12-31: $32.49M$32.49M
2023-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$32.49M-87.4%2026-02-27, Balance as of period end
2024-12-31$257.07Mn/m2026-02-27, Balance as of period end
2023-12-31$8.27Mn/a2025-03-28, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
CG Oncology, Inc. (CGON)2025-12-31$32.49M-87.4%
Prime Medicine, Inc. (PRME)2025-12-31$63.03M-65.5%
CRISPR Therapeutics AG (CRSP)2025-12-31$347.56M+16.5%
Surrozen, Inc. (SRZN)2025-12-31$89.25M+158.2%
Dyadic International Inc (DYAI)2025-12-31$4.62M-29.0%
DBV Technologies S.A. (DBVT)2025-12-31$194.17M+498.2%
Fate Therapeutics Inc (FATE)2025-12-31$46.63M+29.3%
Aligos Therapeutics, Inc. (ALGS)2025-12-31$18.30M-50.5%
Humacyte, Inc. (HUMA)2025-12-31$50.50M+12.4%

Compare CGON, PRME, CRSP, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗